The French, American, and British (FAB) classification system for acute myeloid leukemia (AML) is extensively used and is incorporated into the AML, not otherwise specified (NOS) category in the 2016 WHO edition of myeloid neoplasm classification. While recent data proposes that FAB classification does not provide additional prognostic information for patients for whom NPM1 status is available, it is unknown whether FAB still retains a current prognostic role in predicting outcome of AML patients undergoing allogeneic stem cell transplantation. Using the European Society of Blood and Bone Marrow Transplantation registry we analyzed outcome of 1690 patients transplanted in CR1 to determine if FAB classification provides additional prognostic value. Multivariate analysis revealed that M6/M7 patients had decreased leukemia free survival (hazard ratio (HR) of 1.41, 95% confidence interval (CI), 1.01-1.99; P 5 .046) in addition to increased nonrelapse mortality (NRM) rates (HR, 1.79; 95% CI, 1.06-3.01; P 5 .028) compared with other FAB types. In the
| I N T R O D U C T I O N
Prognostication plays a major role in clinical decision-making for patients with acute myeloid leukemia (AML). With the advent of widespread high throughput molecular sequencing platforms, assessment of FLT3 and NPM1 mutational status has become a standard major determinant in predicting patient outcome. As ASCT is associated with significant rates of attendant toxicity and mortality, 1 efforts to better prognosticate and risk stratify patients before transplant are of prime importance. Previous efforts aiming at delineating the role FLT3-ITD status [2] [3] [4] [5] [6] [7] [8] and NPM1 status [9] [10] [11] play in determining clinical outcome following ASCT have yielded conflicting results, thus underscoring the need for improved prognostication of candidates for ASCT. The
French-American-British (FAB) classification system has been traditionally used to classify AML into discrete types designated M0-M7, and notwithstanding the incorporation of new molecular categories into the recent 2016 rendition of the world health organization (WHO) myeloid neoplasms classification, 12 FAB classification is still a core feature of the large WHO category of AML, not otherwise specified (NOS) patients. While earlier studies suggested a prognostic role for specific FAB types, [13] [14] [15] [16] [17] the prognostic role FAB classification holds in current practice has been recently questioned by Walter et al. who propose that when NPM1 and CEBPA status is available, FAB no longer predicts patient outcome. 18 Yet, it remains unclear whether in patients undergoing allogeneic stem cell transplant (ASCT) in complete remission (CR1), FAB still holds prognostic significance. To this end, using the European Society of Blood and Bone Marrow Transplantation (EBMT) registry, we set out to determine whether FAB classification still retains a significant role in the current era of advanced molecularly incorporated classification systems of AML.
| P A T I E NT S A ND M E T H O DS

| Study population
Data were provided, and the study design was approved by the acute leukemia working party (ALWP) of the EBMT group registry, in accordance with the EBMT guidelines for retrospective studies. EBMT is a voluntary working group of more than 500 transplant centers which are required to report all consecutive stem cell transplantations and follow-up once a year. Audits are routinely performed to determine the accuracy of the data. Using the EBMT registry we identified patients with available FAB data and the following inclusion criteria: (1) age over 18, (2) de novo non-M3 AML, and (3) ASCT in complete remission (CR1) from a fully matched sibling or a 10/10 human leukocyte antigen (HLA) matched unrelated donor. Patients with recurrent genetic abnormalities, AML with myelodysplasia-related changes, and patients with therapy-related myeloid neoplasms were excluded from the analysis.
| Endpoint definitions
The primary end points were leukemia-free survival (LFS), relapse incidence (RI), nonrelapse mortality (NRM), and overall survival (OS).
\Secondary end points were engraftment, acute and chronic graftversus-host disease (GVHD). LFS was defined as survival with no evidence of relapse or progression. Relapse was defined as the reappearance of 5% bone marrow blasts and/or extramedullary lesion due to specific blast cell infiltration. NRM was defined as death without evidence of relapse or progression. OS was defined as the time from ASCT to death, regardless of the cause.
| Statistical analysis
Multivariate analyses were used to assess whether the FAB type was independently associated with LFS, OS, RI, and NRM. Age, gender, cytogenetics, donor type, FMS-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) status, nucleophosmin (NPM1) status, and conditioning intensity were covariates for regression modeling. Cytogenetic risk groups were defined according to established criteria. 19 Table 3 and Supporting Information Figure 1 showed that in As shown in Supporting Information Table 4 in which M0 serves as the reference considered to have a hazard ratio of 1.0, a multivariate analysis confirmed that FAB types M2 and M4 were independently associated with decreased LFS rates whereas M4 and M6/M7 had lower OS rates, and M2 patients had an increased likelihood of RI.
There was no statistically significant difference in outcome between M6/M7 patients and non M6/M7 patients in the FLT3-ITD 1 cohort (Supporting Information Figure 2 ).
| DISCUSSION
In the present analysis of 1690 AML patients undergoing allogeneic stem cell transplantation in CR1, we present data supporting a contemporary role for FAB classification in the prediction of posttransplantation outcome. Our findings indicate that in specific patient subsets; eg M6/M7 in an unselected cohort, M6/M7 in the strictly defined AML, NOS NPM1 wt subset, and M6/M7 in FLT3-ITD 1 patients, FAB classification has a substantial prognostic value in predicting adverse outcome following allogeneic transplantation.
Since its introduction in the 1970s, FAB classification has played a central role in classification and to some degree prognostication of AML. [20] [21] [22] Subsequently it underwent modifications to accommodate for advances made in immunophenotyping, cytogenetics, and molecular genetics. 23, 24 While the most recent edition of the World Health Organization classification of myeloid neoplasms and acute leukemia, Abbreviations: FLT3-ITD, FMS-like tyrosine kinase-3 internal tandem duplication; MAC, myeloablative conditioning; NPM1, nucleophosmin; RIC, reduced intensity conditioning; WT, wild type. In early studies looking at the prognostic role of FAB in the setting of allogeneic transplantation, M4 and M5 FAB subtypes were found to be associated with an increased relapse rate, 58% versus the 9% seen in M1-M3. 15 In the same vein, registry data from EBMT also established FAB M4 and M5 as adverse risk factors predicting for leukemia relapse. 16 Data published nearly a decade later showed that in a cohort of 91 patients undergoing transplant in CR1 from HLA-identical siblings, overall survival was inferior in M4-M6 FAB subtypes, and transplantrelated mortality was increased in FAB M4-M6 patients. 17 More recent data in postautologous transplantation patients also supports a prognostic role for FAB classification, wherein M0/M6/M7 patients experienced significantly decreased overall survival compared with M1-M5
patients. 14 Our experience differs from that published by the European and Italian cooperative groups in the EORTC-GIMEMA AML 8A trial where 169 patients underwent ASCT in CR1 and where FAB type was not found to be of prognostic importance. 25 However, we do note that given our much larger and more recent cohort, our data may reflect more accurately the typical contemporary transplant patient population.
Additionally, the aforementioned study did not have molecular data which undoubtedly adds prognostic depth to our analysis. In addition to the different study populations (transplanted vs.
unknown) analyzed, the difference in the results of both studies may be also accounted by acknowledgment of the different complementary molecular data used, ie, FLT3-ITD compared with CEBPA testing.
An additional salient point we establish is that in FLT3-ITD Recently published data also aiming to stratify FLT3-ITD patients being transplanted indicates that patients with a low FLT3-ITD mutation burden (quantified by the FLT3-ITD mutant to wild-type allelic ratio) do not derive a clinical benefit from an ASCT in terms of RFS and OS. 29 However, this assay may be limited by low sensitivity, heterogeneous methodologies, and diverse cutoff values used by different centers. 27 Additionally, our data may better inform clinicians in selecting higher risk patients who may benefit from enrollment into ongoing and future clinical trials with FLT3 targeted maintenance therapy post-transplant.
Given the inherent limitation of a retrospective analysis it may be difficult to determine why FAB M6/M7 patients have decreased leukemia free survival and increased nonrelapse mortality, yet considering that M6
is commonly associated with poor-risk cytogenetics may provide a partial explanation for this clinical phenotype 30 as well as recognizing that FAB M7 has the highest frequency of cytogenetic aberrations among all FAB categories. 31 Nevertheless, we do acknowledge that these would not fully explain the increased non-relapse mortality rates observed in our study.
We recognize several limitations in our analysis. First, the retrospective nature of this study with the inherent limitations seen in comparable analyses. Second, our registry is not fully annotated for CEBPA thus limiting our ability to fully characterize the role of FAB classification per the recently revised WHO classification. Lastly, the relative infrequency of FAB M6/M7 in general and specifically in our analyzed cohort may also limit interpretation of our data.
In aggregate, our findings in a large cohort of transplanted patients suggest that FAB classification contributes and enhances the prognostic capacity of molecular data provided by FLT3-ITD and NPM1 mutational status. Our findings support the continued use of FAB classification to complement molecular data in AML patients undergoing allogeneic stem cell transplantation.
